Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.
Soligenix, Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company headquartered in Princeton, New Jersey. The company is dedicated to developing and commercializing products that address unmet medical needs, particularly in the areas of inflammation, oncology, and biodefense. Soligenix operates through two business segments: Specialized BioTherapeutics and Public Health Solutions.
Under the Specialized BioTherapeutics segment, Soligenix focuses on rare disease treatments. Key projects include HyBryte™ (SGX301), a novel photodynamic therapy using synthetic hypericin for cutaneous T-cell lymphoma (CTCL). HyBryte™ has shown promising results in Phase 3 clinical trials and is on track for regulatory approvals in the United States and Europe. Other development programs include SGX302 for psoriasis, SGX942 for oral mucositis in head and neck cancer, and SGX945 for Behçet's disease.
The Public Health Solutions segment emphasizes vaccine development and biodefense. Notable projects include RiVax®, a ricin toxin vaccine candidate, and thermostable vaccine candidates for filoviruses such as Marburg and Ebola. These vaccines are developed using the company's proprietary heat stabilization platform technology, ThermoVax®. Soligenix has also been active in developing CiVax™, a vaccine candidate for COVID-19.
Recent achievements include additional patents for their trivalent filovirus vaccine platform and positive clinical trial results for HyBryte™. Financially, the company reported a net loss for the quarter ended March 31, 2024, but successfully raised $4.75 million through a public offering. Soligenix has also secured significant non-dilutive government funding to support its various development programs.
Partnerships with esteemed institutions like the University of Hawaiʽi at Mānoa and funding from organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) further bolster Soligenix's research and development efforts. With a robust pipeline and strategic collaborations, Soligenix aims to deliver significant long-term value to its shareholders and address critical healthcare needs globally.
Soligenix, Inc. (Nasdaq: SNGX) announced a Notice of Allowance from the USPTO for its patent application on thermally stable trivalent filovirus vaccines. The vaccine platform combines glycoprotein antigens with nanoemulsion adjuvants, demonstrating efficacy against Ebola and Marburg viruses. It shows stable performance at high temperatures, enhancing storage logistics for vaccine distribution in outbreak scenarios. The vaccine candidate has exhibited protection in non-human primates, and the project is supported by NIH grants.
Soligenix, a late-stage biopharmaceutical company focusing on rare diseases, will present at the H.C. Wainwright Global Investment Conference from May 23 to 26, 2022. Their on-demand presentation is scheduled for May 24 at 7 AM ET. Attendees can schedule one-on-one meetings with Soligenix management during the event. The company is advancing the commercialization of HyBryte™ (SGX301) for cutaneous T-cell lymphoma and developing other therapeutics for various conditions. For more information, visit their website or the conference site.
Soligenix, Inc. (Nasdaq: SNGX) reported its financial results for Q1 2022, with revenues of $0.2 million, up from $0.1 million in Q1 2021. The company incurred a net loss of $4.3 million, increasing from $2.4 million in the previous year. Key upcoming milestones include submitting a New Drug Application for HyBryte™ for cutaneous T-cell lymphoma and initiating a Phase 2a trial for SGX302 in psoriasis. With $22.9 million in cash and government funding support, Soligenix is positioned to advance its product development strategies.
Soligenix, Inc. (Nasdaq: SNGX) announced it has secured approximately $1.4 million in non-dilutive funding through government tax programs. This includes $1.2 million from New Jersey's Technology Business Tax Certificate Transfer Program and $0.2 million from the UK's HMRC R&D Tax Credit Program. Over the past twelve years, Soligenix has received about $7.6 million in non-dilutive funding, supporting its rare disease pipeline. They plan to file a new drug application for HyBryte™, treating cutaneous T-cell lymphoma, later this year.
Soligenix, Inc. (SNGX) reported its financial results for the year ended December 31, 2021, revealing revenues of $0.8 million, down from $2.4 million in 2020. The net loss decreased to $12.6 million ($0.31 per share) from $17.7 million ($0.64 per share) in 2020. Key developments include plans to submit an NDA for HyBryte™ for cutaneous T-cell lymphoma and initiate a Phase 2a trial for SGX302 in psoriasis. Cash reserves stood at $23.3 million, sufficient to support upcoming milestones. The company remains open to strategic partnerships and acquisitions.
Soligenix, Inc. (Nasdaq: SNGX) announced positive results from a study of its CiVax™ COVID-19 booster vaccine in non-human primates. Administered seven months post-primary vaccination, the booster rapidly enhanced neutralizing antibody responses against the Delta and Omicron variants. Antibody levels increased by up to 27-fold within a week and 243-fold within three weeks. CiVax™, supported by a $1.5M SBIR grant from NIAID, showcases broad potential due to its heat-stable formulation, which could simplify global vaccination logistics.
SG Blocks is leading the seed round investment in Moliving, a luxury nomadic hospitality solution, to enhance modular living and hospitality. The funds will support the construction of 60 units for Moliving's flagship hotel in Hudson Valley, with potential for 400 additional units through five planned locations in 2023. This collaboration highlights the synergy between SG Blocks and Moliving, as both aim to meet market demands sustainably. The flagship hotel, Moliving at Hurley House, is set to open in Summer 2022.
Soligenix, Inc. (Nasdaq: SNGX) has announced that Jonathan Guarino, CFO, will present at the Q1 Virtual Investor Summit on March 8, 2022, at 1:15 PM EST. The summit runs from March 8-9 and features one-on-one meetings and company presentations. Attendees can access the presentation through the event platform. Soligenix focuses on treating rare diseases, with products like HyBryte™ for cutaneous T-cell lymphoma and vaccine candidates for various infectious diseases.
Soligenix, a late-stage biopharmaceutical company focused on rare diseases, will present at the BIO CEO & Investor Conference from February 14-17, 2022. The presentation, available on-demand from February 11, will be led by CEO Christopher J. Schaber, PhD. Attendees can also schedule one-on-one meetings with management during the conference. Soligenix is advancing potential treatments like HyBryte™ for cutaneous T-cell lymphoma and RiVax® for ricin toxin exposure. For more details, visit the conference website.
Soligenix (SNGX) provided an update on its strategic plans and development pipeline in a letter from CEO Dr. Christopher J. Schaber. Key upcoming milestones include submitting an NDA for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) and initiating a Phase 2 trial for SGX302 in psoriasis. HyBryte™ shows potential peak U.S. sales exceeding $90 million, with a global psoriasis market opportunity over $1 billion. Additionally, ongoing development of vaccines and the significance of a $20 million partnership with Pontifax were highlighted, ensuring sufficient capital into 2023.
FAQ
What is the current stock price of Soligenix (SNGX)?
What is the market cap of Soligenix (SNGX)?
What does Soligenix, Inc. specialize in?
What are the key projects under Soligenix's Specialized BioTherapeutics segment?
What is ThermoVax®?
What achievements has Soligenix recently made?
Who are some of Soligenix's key partners?
What financial milestones has Soligenix achieved?
What is HyBryte™?
What is CiVax™?
What is RiVax®?
What are Soligenix's key areas of focus in vaccine development?
